Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports.
TRANSCRIPT +
Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports.